847560-46-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylate serves as a building block in the synthesis of various pharmaceuticals. It is utilized as an intermediate in organic synthesis for the development of new chemical entities, particularly those with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, ethyl 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylate is also employed as a building block for the synthesis of agrochemicals, contributing to the development of new compounds with potential applications in agriculture.
Used in Drug Discovery and Development:
ethyl 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylate is recognized for its diverse range of biological activities, making it an important target for drug discovery and development. Research is ongoing to explore its therapeutic applications, particularly in the areas of anti-cancer and anti-inflammatory treatments.

Upstream product

• 5604-46-6 2-amino-4,6-dichloropyrimidine-5-carboxaldehyde 
• 623-51-8 ethyl 2-sulfanylacetate 

Downstream Products

• 847557-42-0 2-amino-4-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 847559-67-5 2-amino-4-(5-benzyloxy-2,4-dichlorophenyl)thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 847558-29-6 2-amino-4-(2,4-dichlorophenyl)thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 1028332-48-0 ethyl 2-amino-4-(2,4-dimethoxy-6-methylphenyl)thieno[2,3-d]pyrimidine-6-carboxylate 
• 847560-62-7 2-amino-4-benzyloxy-thieno[2,3-d]pyrimidine-6-carboxylic acid 
• 1569316-57-9 C₁₆H₁₁FN₄O₂S 
• 847559-68-6 2-amino-4-(2,4-dichloro-5-hydroxyphenyl)thieno[2,3-d]pyrimidine-6-carboxylic acid ethylamide 

Relevant academic research and scientific papers

Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)

Inhibition of multiple signaling pathways in a cancer cell with a single molecule could result in better therapies that are simpler to administer. Efficacy may be achieved with reduced potency against individual targets if there is synergy through multiple pathway inhibition. To achieve this, it is necessary to be able to build multi-component ligands by joining together key pharmacophores in a way which maintains sufficient activity against the individual pathways. In this work, designed triple inhibiting ligands are explored aiming to block three completely different target types: a kinase (JAK2), an epigenetic target (HDAC) and a chaperone (HSP90). Although these enzymes have totally different functions they are related through inter-dependent pathways in the developing cancer cell. Synthesis of several complex multi-inhibiting ligands are presented along with initial enzyme inhibition data against 3 biological target classes of interest. A lead compound, 47, was discovered which had low micromolar activity for all 3 targets. Further development of these complex trispecific designed multiple ligands could result in a ‘transient drug’ an alternative combination therapy for treating cancer mediated via a single molecule.

Combining hit identification strategies: Fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone

Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe novel 2-aminothieno[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors, which were designed

5-6-BICYCLIC HETEROAROMATIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

2-AMINO PYRIDINE COMPOUNDS

The present invention is directed to 2-aminopyrimidine compounds and pharmaceutically acceptable salts thereof, their synthesis and their use as HSP-90 inhibitors.

PYRIMIDOTHIOPHENE COMPOUNDS HAVING HSP90 INHIBITORY ACTIVITY

Compounds of formula (I) are HSP90 inhibitors, of utility in the treatment of, for example, cancers: wherein R1is -(Alk1)p-(Z)r(Alk2)s-Q wherein AIk1 and AIk2 are optionally substituted divalent C1C3 alkylene or C2-C3 alkenylene radicals, p, r and s are independently 0 or 1 , Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO2-, -C(=O)O-, -C(=O)NRA, -C(=S)NRA-, -SO2NRA-NRAC(=O)-, -NRASO2- or -NRA- wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is optionally substituted aryl or heteroaryl; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C-6)alkyl, aryl or heteroaryl radical; and R4 is (i) a carboxylic ester, carboxamide or sulfonamide group, or (ii) a -CN group, or (iii) an optionally substituted C1-C6alkyl, aryl, heteroaryl, aryl(C1-C6alkyl)-, or heteroaryl(C1-C6alkyl)- group, or (iv) a group of formula -C(=O)R5 wherein R5 is hydroxyl, optionally substituted C1-C6alkyl, C1-C6alkyoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl(C1-C6alkyl)-, aryl(C1-C6alkoxy)-, heteroaryl(C1 -C6alkyl)-, or heteroaryl(C1-C-6alkoxy)-, or (v) a group of formula -C(=O)NHR6 wherein R6 is primary, secondary, tertiary or cyclic amino, or hydroxyl, optionally substituted C1-C6alkyl, C1-C6alkyoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl(C1-C6alkyl)-, aryl(C1-C6alkoxy)-, heteroaryl(C1-C6alkyl)-, or heteroaryKC1-C6aikoxy)-.

PYRIMIDOTHIOPHENE COMPOUNDS FOR USE AS HSP90 INHIBITORS

Certain specific compounds of formula (I) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment ofinter alia, cancer: formula (I) wherein R2 is a group of formula -(Ar1)m-(Alk1)P

PYRIMIDOTHIOPHENE COMPOUNDS

Compounds of formula (I) are inhibitors of HSP90, and useful in the treatment of, for example, cancers: Formula (I) wherein R2 is a group of formula (IA): -(Ar1)m (Alk1)P (Z)r (Alk2/s

Synthesis of 2,4-diaminothieno- and pyrrolo[2,3-d]pyrimidine-6-carboxylic acid derivatives

A series of new 2,4-diaminothieno[2,3-d]- and 2,4-diaminopyrrolo[2,3-d] pyrimidine derivatives were synthesised. Reaction of 2-amino-4,6- dichloropyrimidine-5-carbaldehyde (1) with ethyl mercaptoacetate, methyl N-methylglycinate or ethyl glycinate afforde

PYRIMIDOTHIOPHENE COMPOUNDS

Compounds of formula (1) are inhibitors of HSP90 activity in vitroor in vivo, and of use in the treatment of inter alia, cancer: wherein R2 is a group of formula -(Ar1)m-(Alk1)P-(Z)r-(Alk2)